AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00866450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western style diet (high fat and low in calcium)
Description: Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
Study NCT00866450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prudent-style diet (low fat and high in calcium)
Description: Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
Study NCT02198625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate FiO2 and Protective Lung Ventilation Using
Study NCT01095406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S1 ventilation
Description: Ventilation with a O2 and CO2 controller
Study NCT02869282 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Additional blood samples at baseline, 6, 12, 18 and 24 months.
Study NCT02869282 — intervention group
Intervention type: OTHER
Intervention: Urine samples
Description: Additional urine samples at baseline, 6, 12, 18 and 24 months.
Study NCT01815047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplementation
Study NCT02737852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Chameleon Personal Lubricant
Description: silicone base with sensate
Study NCT02055651 — intervention group
Intervention type: BEHAVIORAL
Intervention: Examination and survey
Description: Routine medical examination as required by law and follow-up for lifestyle change program
Study NCT02088112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib QD
Study NCT02088112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV Q2W
Study NCT00665873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PORT-A-CATH (Smiths Medical Inc., MN)
Description: Port a Cath implanted by surgical cut-down
Study NCT00665873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin and clavulanic acid
Description: 1 gr i.v. before the procedure
Study NCT03805945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine group
Description: After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
Study NCT03805945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
Study NCT02154360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
Study NCT04193020 — intervention group
Intervention type: OTHER
Intervention: Surveillance card
Description: Surveillance card and additional examination to find novel markers and better assess the existing ones
Study NCT04041089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition of objects
Description: * Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects
Study NCT04041089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location of objects
Description: * Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible
Study NCT04041089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of objects
Description: * Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)
Study NCT02839408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Description: Sachet containing Lactobacillus rhamnosus SP1
Study NCT02839408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tablet containing 500mg Azithromicyn
Study NCT02839408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Talc powder
Description: Sachet containing talc powder and tablet containing talc powder
Study NCT02839408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment Scaling and root planning
Study NCT02839408 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal treatment Scaling and root planning
Study NCT00399789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: Perifosine will be tested in 3 dose forms
Study NCT02462356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uniportal VATS
Description: Uniportal VATS lobectomy and lymph node dissection will be performed in this group
Study NCT02462356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional VATS
Description: Conventional VATS lobectomy and lymph node dissection will be performed in this group
Study NCT02225470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 (Eribulin Mesylate)
Study NCT02225470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine injection
Study NCT03335163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily
Study NCT03251742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hayek RTX ventilator
Description: Negative pressure ventilation in Fontan patients.
Study NCT03251742 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hayek RTX ventilator
Description: Negative pressure ventilation in Fontan patients.
Study NCT01131533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: vitrectomy following intravitreal erythropoietin
Study NCT00003281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00003281 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01361243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH+
Description: 6 week face-to-face parent intervention.
Study NCT01361243 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Group
Description: 1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
Study NCT01156272 — intervention group
Intervention type: DEVICE
Intervention: ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm
Description: Replacement aortic heart valve
Study NCT03286062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Agent VM110 and laproscopic infra-red probe
Description: Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1a - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and routine vaccine at study month 12.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1b - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2a - Routine and rMenB+OMV NZ vaccines
Description: One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2b - rMenB+OMV NZ and routine vaccines
Description: Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3a - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations
Description: One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4a- rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
Study NCT00847145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4b - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
Study NCT01458912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler
Study NCT01458912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler
Study NCT01458912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 MD
Description: 2 puffs MD b.i.d. via Respimat inhaler
Study NCT01458912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 HD
Description: 2 puffs HD p.m. via Respimat inhaler
Study NCT02623127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT03040440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical endotracheal tube
Description: Cylindrical endotracheal tube was intubated
Study NCT03040440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaperGaurd endotracheal tube
Description: TaperGaurd endotracheal tube was intubated
Study NCT02834221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided puncture
Description: A 7 megahertz ultrasound linear probe will be used.
Study NCT02834221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical landmark guided puncture
Description: Anatomical landmark puncture
Study NCT00836628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT02339909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed financial incentive
Description: Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment.
Study NCT04672278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shanzha Fruit drink or placebo drink
Description: The dosage of Shanzha fruit drink or the placebo is 3 cans per day
Study NCT03018652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
Study NCT03018652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
Study NCT00740649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSD-016
Study NCT02339909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic financial incentive
Description: Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment.
Study NCT02339909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter.
Study NCT01088126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: radiofrequency catheter ablation, NavX system
Study NCT00740649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study NCT03921957 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
Study NCT03883607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80mg
Description: Once daily oral intake of elafibranor 80 mg during 3 months
Study NCT03883607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 120mg
Description: Once daily oral intake of elafibranor 120 mg during 3 months
Study NCT00368953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yukon Choice stent system
Description: coronary stent implantation
Study NCT00368953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberté stent system
Description: coronary stent implantation
Study NCT03761433 — intervention group
Intervention type: DEVICE
Intervention: SPI group
Description: All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
Study NCT00635778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours
Study NCT03366896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Malay 3D-CAM diagnostic tool 1
Description: Assessor 1 uses Malay 3D-CAM to detect Delirium
Study NCT03366896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Malay 3D-CAM Diagnostic tool 2
Description: Assessor 2 uses Malay 3D-CAM to detect Delirium
Study NCT00148317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
Study NCT00148317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
Study NCT00148317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
Study NCT00148317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophoshamide
Description: During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
Study NCT00148317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
Study NCT04273737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
Study NCT02472470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
Study NCT02693366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell
Description: Endovascular infusion of bone marrow derived cells in both renal arteries.
Study NCT01817556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stillen Tab.
Study NCT03821402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 250 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
Study NCT03821402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 375 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Study NCT03821402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI for injection 500 U
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
Study NCT03821402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study NCT06016049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA® adjuvant
Description: cutaneous forearm deafferentation
Study NCT01817556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta Tab.
Study NCT03146091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonantibiotic treatment of uncomplicated diverticulitis
Description: Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
Study NCT03146091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment of uncomplicated diverticulitis
Description: Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
Study NCT02750761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (IV)
Description: 200 mg/vial powder for injection
Study NCT06016049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensory training
Description: Sensibility training of the median nerve
Study NCT06016049 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sensory training
Description: Sensibility training of the median nerve
Study NCT02750761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (oral suspension)
Description: Powder for oral suspension 20 mg/mL following reconstitution
Study NCT00424489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Autologous Hematopoietic Stem Cell Transplantation
Study NCT00424489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00424489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (rabbit)
Study NCT00424489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Study NCT00424489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00424489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate nasal spray, 200 mg once daily
Study NCT01777386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preexpanded perforator flap surgery
Study NCT04937218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg demand creation campaign
Description: Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
Study NCT04086901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose escalation
Description: Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
Study NCT03882047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate nasal spray, 200 mg once daily
Study NCT03529032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: methadone for control postoperative pain